Tarsus Pharmaceuticals, Inc.
TARS
$59.10
-$0.73-1.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 72.27% | 63.77% | 46.26% | 38.90% | 29.70% |
| Total Depreciation and Amortization | -5.00% | 2.55% | 61.97% | 89.54% | 70.37% |
| Total Amortization of Deferred Charges | 14.39% | 13.04% | 17.83% | 44.55% | 21.93% |
| Total Other Non-Cash Items | 93.69% | 122.22% | 69.10% | -19.11% | -5.97% |
| Change in Net Operating Assets | -1,443.25% | 337.04% | 144.41% | -259.53% | 77.76% |
| Cash from Operations | -19.37% | 187.14% | 311.01% | -104.02% | 45.35% |
| Capital Expenditure | -886.10% | -8,730.56% | -577.30% | 3.66% | -239.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -53.54% | 193.50% | -183.08% | -28.41% | 66.34% |
| Cash from Investing | -67.60% | 182.71% | -251.63% | -27.59% | 65.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.12% | -21.01% | 277.88% | -27.16% | 37.38% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.12% | -21.01% | 300.94% | -95.39% | 25.55% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -201.29% | 189.96% | 429.09% | -527.59% | 359.17% |